173 related articles for article (PubMed ID: 37560283)
1. Edoxaban treatment in atrial fibrillation in routine clinical care: One-year outcomes of the prospective observational ETNA-AF study in South Korean patients.
Choi EK; Choi JI; Park HS; Hwang GS; Joung B; Kim JY; Kim DH; Shin DG; Park HW
J Arrhythm; 2023 Aug; 39(4):546-555. PubMed ID: 37560283
[TBL] [Abstract][Full Text] [Related]
2. Clinical Events with Edoxaban in South Korean and Taiwanese Atrial Fibrillation Patients in Routine Clinical Practice.
Choi EK; Lin WS; Hwang GS; Kirchhof P; De Caterina R; Chen C; Unverdorben M; Wang CC; Kim YH
J Clin Med; 2021 Nov; 10(22):. PubMed ID: 34830618
[TBL] [Abstract][Full Text] [Related]
3. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of patients initiated on edoxaban in Europe: baseline data from edoxaban treatment in routine clinical practice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe).
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Kerschnitzki M; Reimitz PE; Kirchhof P;
BMC Cardiovasc Disord; 2019 Jul; 19(1):165. PubMed ID: 31299906
[TBL] [Abstract][Full Text] [Related]
5. Prescribing Patterns and Outcomes of Edoxaban in Atrial Fibrillation Patients From Asia - One-Year Data From the Global ETNA-AF Program.
Choi JI; Kiatchoosakun S; Jiampo P; Tse HF; Soo YOY; Wang CC; Lee CH; Pecen L; Unverdorben M; De Caterina R; Kirchhof P
Circ Rep; 2024 Mar; 6(3):86-93. PubMed ID: 38464984
[No Abstract] [Full Text] [Related]
6. Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study.
de Groot JR; Weiss TW; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Waltenberger J; Steffel J; Levy P; Bakhai A; Zierhut W; Laeis P; Manu MC; Reimitz PE; De Caterina R; Kirchhof P
Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f30-f39. PubMed ID: 32790837
[TBL] [Abstract][Full Text] [Related]
7. Edoxaban for stroke prevention in atrial fibrillation and age-adjusted predictors of clinical outcomes in routine clinical care.
Kirchhof P; Pecen L; Bakhai A; de Asmundis C; de Groot JR; Deharo JC; Kelly P; Levy P; Lopez-de-Sa E; Monteiro P; Steffel J; Waltenberger J; Weiss TW; Laeis P; Manu MC; Souza J; De Caterina R
Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):47-57. PubMed ID: 35881467
[TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of Edoxaban in Atrial Fibrillation Patients in Routine Clinical Practice: One-Year Follow-Up from the Global Noninterventional ETNA-AF Program.
De Caterina R; Kim YH; Koretsune Y; Wang CC; Yamashita T; Chen C; Reimitz PE; Unverdorben M; Kirchhof P
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33546442
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with the dosing of edoxaban for stroke prevention in patients with atrial fibrillation from South Korea and Taiwan: 1-year data from the Global ETNA-AF Program.
Chao TF; Hong KS; Lee BC; De Caterina R; Kirchhof P; Reimitz PE; Chen C; Unverdorben M; Wang CC
J Chin Med Assoc; 2021 May; 84(5):485-490. PubMed ID: 33742992
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban Treatment in routiNe clinical prActice in patients with non-valvular Atrial Fibrillation (ETNA-AF) in Iberia: Baseline data.
Monteiro P
Rev Port Cardiol (Engl Ed); 2020 Nov; 39(11):651-662. PubMed ID: 33190965
[TBL] [Abstract][Full Text] [Related]
11. Edoxaban for stroke prevention in atrial fibrillation and factors associated with dosing: patient characteristics from the prospective observational ETNA-AF-China registry.
Guo X; Du J; Yang Y; Wu M; Ou W; Han X; Wang Z; Jin J; Zhang P; Zhang Z; Chen G; Long M; Yin G; Liu T; Wang X; Li D; Chen M; Dong Y; Lai C; Zhang X; Yi Y; Xiang J; Chen C; Unverdorben M; Ma C;
Sci Rep; 2024 Feb; 14(1):2778. PubMed ID: 38307927
[TBL] [Abstract][Full Text] [Related]
12. Incidence and Predictors of Worsening Renal Function in Edoxaban-Treated Atrial Fibrillation Patients Within ETNA-AF-Europe Registry.
Gwechenberger M; Barón-Esquivias G; de Vries TAC; Siller-Matula JM; Manu MC; Souza JAG; Wienerroither S; Pecen L; de Groot JR; De Caterina R; Kirchhof P;
JACC Adv; 2024 Apr; 3(4):100880. PubMed ID: 38939675
[TBL] [Abstract][Full Text] [Related]
13. The global Edoxaban Treatment in routine cliNical prActice (ETNA) noninterventional study program: rationale and design.
De Caterina R; Agnelli G; Laeis P; Unverdorben M; Rauer H; Wang CC; Nakamura M; Chiu KM; Reimitz PE; Koretsune Y; Chen C; Thee U; Kaburagi J; Kim YH; Choi WI; Yamashita T; Cohen A; Kirchhof P
Clin Cardiol; 2019 Dec; 42(12):1147-1154. PubMed ID: 31650560
[TBL] [Abstract][Full Text] [Related]
14. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
Boriani G; De Caterina R; Manu MC; Souza J; Pecen L; Kirchhof P
J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209595
[TBL] [Abstract][Full Text] [Related]
15. Outcomes and Safety of Very-Low-Dose Edoxaban in Frail Patients With Atrial Fibrillation in the ELDERCARE-AF Randomized Clinical Trial.
Akashi S; Oguri M; Ikeno E; Manita M; Taura J; Watanabe S; Hayashi T; Akao M; Okumura K; Akishita M; Yamashita T
JAMA Netw Open; 2022 Aug; 5(8):e2228500. PubMed ID: 35997978
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing surveillance on the clinical use of edoxaban in patients with nonvalvular atrial fibrillation (ETNA-AF-Japan): One-year safety and effectiveness analyses.
Yamashita T; Koretsune Y; Nagao T; Shiosakai K
J Arrhythm; 2020 Jun; 36(3):395-405. PubMed ID: 32528563
[TBL] [Abstract][Full Text] [Related]
17. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and The Netherlands: insights from the ETNA-AF-Europe study.
de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
Acta Cardiol; 2021 Jun; 76(4):431-439. PubMed ID: 33406996
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study.
de Vries TAC; Hemels MEW; Cools F; Crijns HJGM; Yperzeele L; Vanacker P; Blankoff I; Lancellotti P; Mairesse GH; de Veer A; Casado Arroyo R; Catez E; de Pauw M; Vanassche T; de Asmundis C; Kirchhof P; De Caterina R; de Groot JR;
Neth Heart J; 2021 Mar; 29(3):158-167. PubMed ID: 33411231
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Treatment Safety in Patients with Atrial Fibrillation on Edoxaban Therapy in Real-Life in Turkey Study: Design and Rationale.
Önsel Türk U; Alioğlu E; Mavioğlu Z; Diker E; Özpelit E; De Caterina R
Turk Kardiyol Dern Ars; 2022 Mar; 50(2):117-123. PubMed ID: 35400633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
